SCHEMBL4018891

SCHEMBL4018891

O=C(NC1CCN(c2ncnc3cc(Cl)ccc23)CC1)c1cccc(C(F)(F)F)c1F.O=C(NC1CCN(c2ncnc3cc(Cl)ccc23)CC1)c1cccnc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.46
CYP2D6 P10635 1/20 0.46
PAK1 Q13153 6/20 0.44
TAS1R3 Q7RTX0 1/20 0.42
TAS1R1 Q7RTX1 1/20 0.42
TAS1R2 Q8TE23 1/20 0.42
TRPV1 Q8NER1 1/20 0.41
CNR1 P21554 3/20 0.41
RBP4 P02753 1/20 0.41
KIT P10721 1/20 0.41
CNR2 P34972 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CYP3A4 P08684 2/20 0.40
HPGD P15428 1/20 0.40
SUV39H1 O43463 1/20 0.39
PRMT1 Q99873 1/20 0.39
SMYD3 Q9H7B4 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4582099 0.94 CYP1A2 (0.52) CYP1A2CYP2D6PAK1TAS1R3TAS1R1
SCHEMBL4018965 0.89 CYP1A2 (0.54) CYP1A2CYP2D6PAK1CNR1CNR2
SCHEMBL4018993 0.84 CYP1A2 (0.53) CYP1A2CYP2D6PAK1CNR1CNR2
SCHEMBL4168703 0.84 ALDH1A1 (0.51) MEN1KMT2A
SCHEMBL4018334 0.83 TAS1R3 (0.46) CYP1A2PAK1TAS1R3TAS1R1TAS1R2
SCHEMBL4019280 0.81 CYP1A2 (0.54) CYP1A2CYP2D6PAK1CNR1CNR2
SCHEMBL4023244 0.81 CNR1 (0.57) CYP1A2CYP2D6PAK1CNR1CNR2
SCHEMBL4024568 0.79 PAK1 (0.68) CYP1A2CYP2D6PAK1CNR1CNR2
SCHEMBL4024856 0.79 PAK1 (0.67) CYP1A2CYP2D6PAK1CNR1CNR2
SCHEMBL4020867 0.78 CYP1A2 (0.55) CYP1A2CYP2D6PAK1CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2066654-A1 N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS Bayer Schering Pharma AG (DE) 2009-06-10 EP disclosed
WO-2008028691-A1 N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-03-13 WO disclosed